

1
2 Intermediate levels of asymptomatic transmission can lead to
3 the highest levels of epidemic fatalities

4
5 Sang Woo Park¹, Jonathan Dushoff^{2,3,4}, Bryan T. Grenfell^{1,5}, Joshua S. Weitz^{6,7,8,*}

6 **1** Department of Ecology and Evolutionary Biology, Princeton University,
7 Princeton, NJ, USA

8 **2** Department of Biology, McMaster University, Hamilton, ON, Canada

9 **3** Department of Mathematics and Statistics, McMaster University, Hamilton, ON,
10 Canada

11 **4** M. G. DeGroote Institute for Infectious Disease Research, McMaster University,
12 Hamilton, ON, Canada

13 **5** Princeton School of Public and International Affairs, Princeton University,
14 Princeton, NJ, USA

15 **6** School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA

16 **7** School of Physics, Georgia Institute of Technology, Atlanta, GA, USA

17 **8** Institut de Biologie, École Normale Supérieure, Paris, France

18 *Corresponding author: jsweitz@gatech.edu

19 **Abstract**

20 Asymptomatic infections have hampered the ability to characterize and prevent
21 the transmission of SARS-CoV-2 throughout the ongoing pandemic. Even though
22 asymptomatic infections reduce severity at the individual level, they can make population-
23 level outcomes worse if asymptomatic individuals—unaware they are infected—transmit
24 more than symptomatic individuals. Using an epidemic model, we show that interme-
25 diate levels of asymptomatic infection lead to the highest levels of epidemic fatalities
26 when the increase in asymptomatic transmission, due either to individual behavior
27 or mitigation efforts, is strong. We generalize this result to include presymptomatic
28 transmission, showing how intermediate levels of non-symptomatic transmission can
29 lead to the highest levels of fatalities. Finally, we extend our framework to illus-
30 trate how the intersection of asymptomatic spread and immunity profiles determine
31 epidemic trajectories, including population-level severity, of future variants.

32 SARS-CoV-2 has had devastating effects at the population level. However, many
 33 individuals experienced mild cases, making it harder to estimate the magnitude of
 34 spread and fatality rate [1]. The ratio of fatalities to documented cases (the case-
 35 fatality rate, CFR) is typically between 1%–4%, varying across population because
 36 of testing patterns, treatment practice, case definitions, and other factors [2, 3, 4].
 37 But many infections are never documented; the ratio of fatalities to total infections
 38 (the infection fatality rate, IFR) has been estimated to be closer to 0.5%–1% for
 39 pre-vaccinated populations whose demographics are similar to those of the United
 40 States [5]. This means that more than 99% of individuals infected with COVID-19
 41 will survive. Moreover, at least half of the infections are sufficiently mild that they
 42 could be classified as subclinical or even asymptomatic.




Figure 1: **Asymptomatic transmissibility of SARS-CoV-2.** (A) Posterior estimates of the proportion of asymptomatic infections from the Diamond Princess cruise ship [6]. (B) Posterior estimates of the ratio θ_a of the transmission rates between asymptomatic and symptomatic individuals from the Diamond Princess Cruise Ship [6]. Bar charts represent the posterior distributions. Symptomatic individuals were assumed to transmit at rate $\beta(t)$ for an average of 2.9 days, followed by a pre-symptomatic stage with an average of 2.1 days. Asymptomatic individuals were assumed to transmit at rate $\theta_a\beta(t)$ for an average of 5 days. Both estimates are publicly available with further details in [6]. (C) Viral load trajectory data from players, staff, and vendors of the National Basketball Association (NBA). Points represent each Ct measurement. Lines and shaded areas represent the smooth trajectories estimated via LOESS and the associated 95% confidence intervals. Data are publicly available in [7]. (D) Inferred proportion of infections that are subclinical for each age group using surveillance data from six countries (China, Italy, Japan, Singapore, South Korea, and Canada) [8].

43 Early in the pandemic, a COVID-19 outbreak on the Diamond Princess cruise
44 ship played a critical role in understanding the role of asymptomatic infections in the
45 spread of SARS-CoV-2; the outbreak occurred among 3711 passengers and crew, of
46 whom 634 individuals tested positive by 20 February 2020 [9]. It has been estimated
47 that 75% (95% C: 70%-78%) of all infections on the cruise ship were asymptomatic
48 (Fig. 1A) with about half of total infections undetected [6]. The relative transmis-
49 sion rate of asymptomatic individuals aboard the Diamond Princess was not well
50 constrained, but low relative transmission rate (below 25%) by asymptomatic in-
51 dividuals was ruled out because it required unrealistically high transmissibility for
52 symptomatic individuals (Fig. 1B). Modeling studies have typically assumed that
53 transmissibility is lower for asymptomatic than for symptomatic individuals; assump-
54 tions have ranged from 10%–100% [10, 11]. Similarities in viral load trajectories of
55 asymptomatic and symptomatic individuals provide indirect support for the trans-
56 missibility of asymptomatic individuals (Fig. 1C, [7]); however, differences between
57 inferred total viral load from Ct values and infectious viral load add uncertainties
58 to how well asymptomatic individuals can transmit relative to that of symptomatic
59 individuals [12]. We note also that asymptomaticity is expected to be more het-
60 erogeneous in a diversity of outbreak settings [13]. For example, during the early
61 pandemic, Davies *et al.*'s analyses of surveillance data across six countries revealed
62 that older individuals are less likely to have subclinical infections (Fig. 1D), provid-
63 ing indirect evidence for heterogeneity in asymptomaticity [8]. Differences in contact
64 rates between age classes further contribute to the heterogeneity in asymptomatic
65 transmissibility. For now, we primarily focus on a homogeneous population and
66 return to the age effect in discussing our model-based findings.

67 Despite quantitative uncertainties in asymptomatic transmissibility, individuals
68 infected asymptotically with SARS-CoV-2 can still transmit to others. This means
69 that the presence of asymptomatic infections may have countervailing effects at the
70 population level. On one hand, an asymptomatic infection means that the individ-
71 ual infected avoids hospitalization and death. On the other hand, asymptomatic
72 infections are less likely to be detected [14], meaning that asymptomatic individuals
73 are less likely to take precautions and relatively more likely to infect others; asymp-
74 tomatic SARS-CoV-2 infections present additional challenges to managing overall
75 disease burden due to the possibility of long COVID [15]. Altogether, the preva-
76 lence of asymptomatic infections could paradoxically make population-level outcomes
77 worse than if SARS-CoV-2 was more dangerous at the individual level.

78 To explore this idea, we propose a simple epidemic model, in which infected
79 individuals can be asymptomatic or symptomatic, with probabilities p and $1 - p$,
80 respectively (Fig. 2A). Asymptomatic individuals always recover, whereas a fraction
81 f of symptomatic individuals die. Asymptomatic and symptomatic individuals can
82 also have different infection characteristics, including their transmission rates (β_a
83 and β_s) and removal rates (γ_a and γ_s). Our key assumption is that symptomatic
84 individuals take greater precautions than do asymptomatic individuals (e.g., via
85 reducing contacts or increased mask-wearing) and therefore reduce their transmission

86 rate by a fraction δ ; the parameter δ may also capture intervention measures that
87 target symptomatic individuals, such as symptom-based isolation. We note that
88 intervention measures that target asymptomatic infections would reduce the effective
89 value of δ —for example, frequent testing and isolation may effectively increase the
90 removal rate γ_a of asymptomatic individuals. For our main simulations, we assume
91 that asymptomatic individuals have a lower reproduction number—this is modeled
92 by assuming lower transmission rates for asymptomatic individuals ($\beta_a = 0.75\beta_s$)
93 and equal removal rates ($\gamma_a = \gamma_s$). We evaluate the effects on population-level
94 mortality of changing the asymptomatic proportion p while holding the fatality rate
95 for *symptomatic* cases, f , constant (the IFR $(1-p)f$ thus decreases as p increases).

96 Fig. 2B–C shows simulated epidemic outcomes using parameters similar to those
97 of the originating strain of SARS-CoV-2, without any mitigation other than that
98 individuals who are symptomatic reduce their transmission rate by δ . For this model,
99 the basic reproduction number is given by:

$$\mathcal{R}_0 = (1-p)(1-\delta)\mathcal{R}_s + p\mathcal{R}_a, \quad (1)$$

100 where $\mathcal{R}_s = \beta_s/\gamma_s$ and $\mathcal{R}_a = \beta_a/\gamma_a$ represent the reproduction numbers of asymp-
101 tomatic and symptomatic individuals (i.e., the average number of secondary in-
102 fections caused by asymptomatic and symptomatic individuals); therefore, in the
103 absence of the behavioral effect ($\delta = 0$), the final size decreases with the asymp-
104 tomatic proportion p because more symptomatic infections leads to a higher basic
105 reproduction number. This relationship changes as δ increases. In particular, when
106 $\delta > 1 - \mathcal{R}_a/\mathcal{R}_s$ (in this case, $\delta > 0.25$), the basic reproduction number (and thus
107 epidemic size) increases with p because the effective symptomatic reproductive num-
108 ber (including behavioral response) is less than that the asymptomatic reproductive
109 number. For high values of δ , we can find a critical level of asymptomatic proportion,
110 p_c :

$$p_c = \frac{1 - (1-\delta)\mathcal{R}_s}{\mathcal{R}_a - (1-\delta)\mathcal{R}_s} \quad (2)$$

111 such that $p > p_c$ is required for an outbreak (see threshold effects for large values of
112 δ in Fig. 2B).

113 When behavioral protection is high, the effect of asymptomatic proportion on
114 fatalities shows countervailing effects of individual-level protection and population-
115 level risk (Fig. 2C). For high values of δ , the peak fatality occurs at intermediate
116 levels of asymptomatic spread: although fewer individuals die per infection for higher
117 values of p , the increase in total infections also leads to an increase in total fatalities.
118 In contrast, when δ is small enough such that $(1-\delta)\mathcal{R}_s \geq \mathcal{R}_a$ (in this case, $\delta < 0.25$),
119 then total fatalities decrease with p because both the number of infections
120 and the IFR $((1-p)f)$ decrease with increasing p .

121 High values of δ required for the nonlinear effects of asymptomaticity on deaths
122 may seem unrealistic. For this particular model, it does not make biological sense
123 for δ to be greater than the amount of post-symptomatic transmission, because




Figure 2: Schematic diagram and simulations of a model with asymptomatic transmission and symptom-responsive transmission reduction. (A) S represents susceptible individuals; E represents exposed individuals; I_a represents asymptomatic individuals; I_s represents symptomatic individuals; R represents recovered individuals; and D represents deceased individuals. See Methods for model details. (B) Total infections as a function of the proportion of asymptomatic infections p across a wide range scenarios for δ . (C) Total deaths as a function of the proportion of asymptomatic infections p across a wide range scenarios for δ . We simulate the model for 365 days, assuming $\beta_s = 0.8/\text{day}$, $\beta_a = 0.75\beta_s$, $\nu = 0.5/\text{day}$, $\gamma_s = \gamma_a = 0.2/\text{day}$, and $f = 0.01$, and an initial exposed proportion of 10^{-4} . See Supplementary Text for model details and Supplementary Table S1 for parameter descriptions and values.

124 pre-symptomatic transmission is implicitly included in the I_s compartment. While
 125 several studies have estimated the proportion of pre-symptomatic transmission to
 126 be around 30%–60% for the SARS-CoV-2 wildtype strain, many of these were likely
 127 affected by intervention and behavioral effects, as they were conducted after SARS-

128 CoV-2 awareness became widespread [16]. Instead, [17] recently estimated that the
129 proportion of pre-symptomatic transmission could have been as low as 20% (95%CI:
130 6%–32%) during the first few weeks of the pandemic when the pandemic-awareness
131 and intervention measures were minimal. There are two implications of this updated
132 estimate—first, a low proportion of pre-symptomatic transmission suggests that high
133 δ values are feasible (although not necessarily likely) during the initial pandemic
134 phase; and second, intermediate levels of behavioral effects ($\delta > 0$) would have been
135 already present early in the pandemic to reduce the proportion of pre-symptomatic
136 transmission from 80% to as low as 40%.

137 We therefore extend our model to consider the effects of generalized *non-symptomatic*
138 transmission, which includes both pre-symptomatic and asymptomatic transmission,
139 to ask the following question: does an intermediate amount of non-symptomatic
140 transmission lead to a peak in fatalities? For this model, we assume that δ decreases
141 transmission only after symptom onset. We then fix the reproduction number of
142 symptomatic individuals and calculate fatalities at the population level as a func-
143 tion of the proportion of total non-symptomatic transmission and the proportion
144 of non-symptomatic transmission that is caused by pre-symptomatic transmission
145 (see Supplementary Text for model details and Supplementary Table S2 for param-
146 eter descriptions and values). Using the generalized non-symptomatic transmission
147 model, we find a wide variety of scenarios for which peak fatalities occur at interme-
148 diate levels of non-symptomatic transmission in the presence of moderate to strong
149 behavioral effects, $\delta > 0.6$ (Supplementary Figure S1). One exception is the ex-
150 treme (and unrealistic) case, in which all non-symptomatic transmission is caused
151 by pre-symptomatic transmission (i.e., there are no asymptomatic cases); in this
152 case, total infections and fatalities are maximized when all transmission is caused
153 by pre-symptomatic transmission. Hereafter, we focus on asymptomatic infections
154 for simplicity, but our conclusions have implications for the more general case of
155 non-symptomatic transmission.

156 We now apply our framework to understand the impact of immunity on total
157 fatalities at the population scale by dividing the population into two groups: im-
158 munologically naive and protected. For simplicity, we do not distinguish whether
159 the immunity is derived from natural infections or vaccines. The dynamics of im-
160 munologically naive individuals are equivalent to our original model (Fig. 2). The
161 dynamics of protected individuals include three additional parameters, which char-
162 acterize the amount of protection against infection ϵ_i , symptoms (given infection)
163 ϵ_s , and deaths (given symptoms) ϵ_d (Fig. 3). For simplicity, we assume that the
164 population is split in half (50% naive and 50% protected) and mixes homogeneously.
165 We also do not consider the separate effect of immunity on transmission (beyond
166 the effect on infection). In other words, we assume that asymptomatic infections in
167 protected and unprotected people have the same reproduction numbers (and likewise
168 for the symptomatic infections). In practice, both asymptomatic and symptomatic
169 infections in protected people are less likely to transmit than their unprotected coun-
170 terparts [18]: asymptomatic infections in protected people may indicate limited viral

171 replication or even immune boosting, in which case an exposed individual may suc-
172 cessfully fight off the pathogen early in infection before it can be transmitted; and
173 symptomatic infections in protected people may reflect a strong immune response
174 (rather than high viral load), in which case symptomatology can be a poor proxy for
175 transmission. We assume a relatively strong behavioral effect $\delta = 0.8$ for illustration.

176 We consider each protection effect— ϵ_i , ϵ_s , and ϵ_d —separately and consider joint
177 effects later on. The impact of protection against infection ϵ_i is analogous to changing
178 \mathcal{R}_0 in the original model: as immunity provides stronger protection against infection
179 (higher ϵ_i), the number of deaths decreases and a higher asymptomatic fraction p
180 is required for the infection to spread (Fig. 3B). We note that protection against
181 infection scales the fatality curve nonlinearly, reflecting the nonlinear relationship
182 between \mathcal{R}_0 and the final size of the outbreak. The impact of protection against
183 symptoms ϵ_s is equivalent to changing the asymptomatic fraction p for the protected
184 population because protected individuals are less likely to develop symptoms: the
185 peaks of the fatality curves move to lower values of p as we increase the degree of
186 protection ϵ_s (Fig. 3C). Therefore, for low values of p , protection against symptoms
187 can increase the total number of fatalities at the population level by increasing the
188 proportion (and number) of asymptomatic individuals, who can readily transmit in-
189 fections to other individuals. This also means that the critical level of asymptomatic
190 proportion decreases, allowing more dangerous infections (with lower p) to invade,
191 which would not have been able to spread in an otherwise immunologically naive pop-
192 ulation. We note that the equivalence between protection against symptoms ϵ_s and
193 fraction asymptomatic p relies on our assumption that immunity does not provide
194 protection against transmission. Protection against deaths ϵ_d directly modulates the
195 fatality rate for symptomatic cases and therefore linearly scales the fatality curves
196 (Fig. 3D).

197 Finally, we use our framework to understand the impact of behavioral effects
198 on invading variants (Fig. 4). In doing so, we first simulate the dynamics of a
199 wildtype variant for 1 year using our base model using identical parameters as in
200 Fig. 2. We then simulate a new variant invading a partially immune population using
201 our extended model (Fig. 3A), where the immunity is solely derived from natural
202 infections caused by the wildtype variant in the first year. We consider two types of
203 variants (which are simulated separately): one with the same severity p (variant 1,
204 orange) and a milder one with higher p (variant 2, purple).

205 First, we consider a scenario in which immunity only provides protection against
206 symptoms, $\epsilon_s = 0.4$ (Fig. 4A–C). In this case, protection against symptoms allows
207 new variants to spread faster by increasing the amount of asymptomatic infections,
208 resulting in larger outbreaks (Fig. 4B). Although the milder (purple) variant exhibits
209 a faster epidemic growth rate and reaches a higher peak (Fig. 4B), it reaches similar
210 peak fatality as the more severe (orange) variant (Fig. 4C). The asymptomaticity–
211 fatality curve provides additional insight (Fig. 4A): even though a milder, invading
212 variant (purple square) gives higher peak fatality than the original, wildtype variant
213 (black circle), it leads to lower fatalities overall because deaths are concentrated over




Figure 3: Schematic diagram and simulations of a model with symptom-responsive transmission reduction and immunity. (A) The subscript p represents protected individuals. Immunity may provide protection against infection, symptoms, or deaths. The dynamics of immunologically naive individuals are described in Fig. 2. (B–D) Total deaths as a function of the proportion of asymptomatic infections p across a wide range scenarios for protection against infection ϵ_i (B), symptoms ϵ_s (C), and deaths ϵ_d (D). We simulate the model for 365 days, assuming $\beta_s = 4/5/\text{day}$, $\beta_a = 0.75\beta_s$, $\nu = 1/2/\text{day}$, $\gamma_s = \gamma_a = 1/5/\text{day}$, $f = 0.01$, and $\delta = 0.8$. We assume that 10^{-4} proportion of individuals are initially infected. See Supplementary Text for model details and Supplementary Table S3 for parameter descriptions and values.

214 a shorter period of time in the epidemic. In general, when δ is large, invading vari-
 215 ants with similar asymptomaticity p will spread more effectively and result in worse
 216 population-level outcomes if immunity (either from vaccination or natural infection)
 217 provides protection against symptoms but not against infection or transmission.




Figure 4: **Dynamics of invading variants under symptom-responsive transmission reduction and immunity.** (A, D) Asymptomaticity–fatality curves for the first (solid lines) and second waves (dashed lines). Points represent specific scenarios we assume for the first and second waves. Fatality curves for the first wave are calculated by simulating an epidemic for 1 year using parameters from Fig. 2 with $\delta = 0.8$. Fatality curves for the second wave are calculated by first simulating the first wave assuming $p = 0.2$ for 1 year to calculate the proportion immune and then simulating the extended model presented in Fig. 3 for two different values of p as shown. (B, E) Dynamics of infection prevalence for the wildtype variant (black, solid line) and two possible invading variants (colored, dashed line). (C, F) Dynamics of daily deaths for the wildtype variant (black, solid line) and two possible invading variants (colored, dashed line).

218 Next, we consider a more realistic scenario in which immunity provides protection
 219 against both symptoms, $\epsilon_s = 0.4$, and infection, $\epsilon_i = 0.4$ (Fig. 4D–F). In this case,
 220 cross-protection against infection has a large effect on the more severe (orange) vari-
 221 ant, causing its peak infection prevalence (Fig. 4E) and fatality (Fig. 4F) to be lower
 222 than that of the original, wildtype variant. Across a wide range of asymptomatic

223 proportion p , we find that this immunity profile is sufficient to prevent worse out-
224 comes at the population level; we note that the second wave of deaths is still high
225 (and having higher peaks in some cases) even if the overall deaths are lower.

226 The outcomes in our simulations of invading variants resemble the dynamics of
227 the SARS-CoV-2 Omicron variant. Despite moderate levels of vaccine effectiveness
228 against symptomatic and reduced levels of severe cases caused by the Omicron vari-
229 ant, especially after booster shots [19], both vaccine- and infection-derived immunity
230 provided limited protection against infections [20]. This immune evasion helped the
231 Omicron variant to cause more infections in South Africa than previous variants [21].
232 Moreover, even though the Omicron variant is probably milder than the Delta variant
233 [22, 23], the number of hospitalizations and deaths caused by the Omicron variant
234 was higher than those caused by the Delta variant in many locations [24, 25, 26].

235 There are several limitations to our analysis. First, while we are able to gener-
236 alize the model to include both pre-symptomatic and asymptomatic transmission,
237 behavioral and intervention effects must be relatively large in order for the fatality
238 to peak at intermediate levels of asymptomaticity (typically requiring a reduction in
239 transmission rate of 60% or more for most of our chosen parameter sets). Second,
240 the model framework is able to incorporate the impacts of immunity of infection,
241 symptoms, and severity, but we neglected the effects of immunity on transmission,
242 which also has important effects on disease dynamics [27]. In particular, if immu-
243 nity provides stronger protection against transmission among immune individuals,
244 population-level outcomes will be better than what our model predicts. Estimating
245 protection against different endpoints (e.g., infection, symptom, death, and trans-
246 mission) can help narrow this uncertainty. Finally, we assumed that asymptomatic
247 and symptomatic individuals are infected for the same amount of time. Analysis of
248 viral load trajectories suggests that asymptomatic individuals may clear infections
249 faster [7]; however, asymptomatic individuals may still transmit for a longer period
250 of time if symptomatic individuals self-isolate quickly after symptom onset. The
251 individual-level differences in the asymptomatic and symptomatic transmission time
252 scale can have important implications for the inferences and predictions of pathogen
253 dynamics [28, 29]; nonetheless, we expect that predictions on the final size of the
254 epidemic and total fatalities will be robust to small differences in the transmission
255 time scale between asymptomatic and symptomatic individuals.

256 Even though we assumed a homogeneous population throughout, our analysis
257 also has important implications for age-dependent heterogeneity in asymptomaticity
258 (as shown in Fig. 1D). For example, vaccinations and intervention measures primarily
259 targeting older individuals can prevent severe infections and improve individual-level
260 outcomes. However, asymptomatic individuals, especially younger individuals with
261 high contact rates, can still transmit to other, older individuals, potentially making
262 population-level outcomes worse than they would be if intervention measures were
263 distributed differently. We note that other factors, such as the efficacy of a vaccine
264 and types of immunity provided by the vaccine, also play critical roles in making
265 these decisions—in many cases, protecting the most vulnerable will be the optimal

266 decision to minimize deaths [30].

267 In summary, using a series of simplified models, we have shown that asymp-
268 tomatic infections (or, more generally, non-symptomatic transmission) can represent
269 a double-edged sword leading to a better outcome for many individuals while facil-
270 itating onward transmission that leads to a worse outcome for the population as a
271 whole. Extending our framework further shows that immunity profile (i.e., reduc-
272 tion of infection, symptoms, and/or severity due to immunity) plays a critical role in
273 determining the dynamics of future variants. For example, while protection against
274 symptoms unaccompanied by protection against transmission protects health at the
275 individual level, it can lead to more infections, and potentially more deaths, at the
276 population level. A similar concern was raised in prioritizing vaccine choices that
277 could reduce severe outcomes vs. others that could reduce transmission [31].

278 SARS-CoV-2 has proven hard to control in large part because transmission is of-
279 ten decoupled from symptoms. Our model reinforces the need for dual approaches—
280 prioritizing the reduction of asymptomatic spread (e.g., via risk awareness cam-
281 paigns [32, 33], asymptomatic testing programs [34, 35], mask-wearing indoors and in
282 crowded environments [36, 37, 38], and through improvements in ventilation [39, 40])
283 while improving the treatment of symptomatic cases, particularly amongst older indi-
284 viduals at highest risk for severe outcomes. Given the link between age and asymp-
285 tomatic infections [8], interventions may consider different approaches in strongly
286 age-structured populations (e.g., schools or long-term care facilities). Mass vacci-
287 nation is also expected to be important especially if future vaccines induce more
288 transmission blocking. As more variants continue to emerge, monitoring the impacts
289 of preexisting immunity (whether through vaccination and/or infections) on prevent-
290 ing infections, and not just diseases, will be critical to controlling the course of the
291 pandemic [41].

292 **Acknowledgements**

293 JSW acknowledges support from the Chaire Blaise Pascal Program of the Île-de-
294 France region. The funders had no role in study design, data collection and analysis,
295 decision to publish, or preparation of the manuscript.

296 **Data availability**

297 All data and code are stored in a publicly available GitHub repository (<https://github.com/parksw3/asymptomaticvariant>).
298

299 Supplementary Text

300 Epidemic models with asymptomatic infection and transmis- 301 sion in the absence of immunity

First, we consider a compartmental model with asymptomatic and symptomatic infections in a homogeneously mixing population. The model dynamics are as follows:

$$\dot{S} = -\beta_a S I_a - (1 - \delta) \beta_s S I_s \quad (3)$$

$$\dot{E} = \beta_a S I_a + (1 - \delta) \beta_s S I_s - \nu E \quad (4)$$

$$\dot{I}_a = p \nu E - \gamma_a I_a \quad (5)$$

$$\dot{I}_s = (1 - p) \nu E - \gamma_s I_s \quad (6)$$

$$\dot{R} = \gamma_a I_a + (1 - f) \gamma_s I_s \quad (7)$$

$$\dot{D} = f \gamma_s I_s \quad (8)$$

302 where the transmission rate β and removal rate γ can be potentially differ between
303 asymptomatic and symptomatic individuals. Here, δ denotes the reduction in trans-
304 missibility due to responsive measures taken by symptomatic individuals. Through-
305 out the paper, we use parameters that are broadly consistent with the dynamics of
306 the originating strain of SARS-CoV-2: $\beta_s = 0.8/\text{day}$, $\beta_a = 0.75\beta_s$, $1/\nu = 2$ days,
307 $1/\gamma_s = 1/\gamma_a = 5$ days, and $f = 0.01$ [42]. Under this parameterization, we have
308 symptomatic and asymptomatic reproduction numbers of $\mathcal{R}_s = 4$ and $\mathcal{R}_a = 3$.

We then extend the first model to include both pre-symptomatic and asymptomatic transmission:

$$\dot{S} = -\beta_p I_p - \beta_a S I_a - (1 - \delta) \beta_s S I_s \quad (9)$$

$$\dot{E} = \beta_a S I_a + (1 - \delta) \beta_s S I_s - \nu E \quad (10)$$

$$\dot{I}_p = \nu E - \sigma I_p \quad (11)$$

$$\dot{I}_a = p \sigma I_p - \gamma_a I_a \quad (12)$$

$$\dot{I}_s = (1 - p) \sigma I_p - \gamma_s I_s \quad (13)$$

$$\dot{R} = \gamma_a I_a + (1 - f) \gamma_s I_s \quad (14)$$

$$\dot{D} = f \gamma_s I_s \quad (15)$$

309 For this model, the pre-symptomatic \mathcal{R}_p , symptomatic \mathcal{R}_s , and asymptomatic \mathcal{R}_a
310 reproduction numbers are given by $\mathcal{R}_p = \beta_p/\sigma$, $\mathcal{R}_s = \beta_s/\gamma_s$, and $\mathcal{R}_a = \beta_a/\gamma_a$ in the
311 absence of the behavioral effect; these reproduction numbers represent the average
312 number of secondary cases caused by an infected individual in each compartment.
313 Then, the reproduction number of individuals who will eventually develop symptoms
314 is equal to: $\mathcal{R}_p + \mathcal{R}_s$; similarly, the reproduction number of individuals who remain
315 asymptomatic is equal to: $\mathcal{R}_p + \mathcal{R}_a$. Since the proportion p of all infections is

316 asymptomatic, the basic reproduction number is given by the weighted average of
317 these two reproduction numbers:

$$\mathcal{R}_0 = p(\mathcal{R}_p + \mathcal{R}_a) + (1 - p)(\mathcal{R}_p + \mathcal{R}_s) = \mathcal{R}_p + p\mathcal{R}_a + (1 - p)\mathcal{R}_s. \quad (16)$$

318 Then, the proportion of non-symptomatic transmission ϕ is given by:

$$\phi = \frac{\mathcal{R}_p + p\mathcal{R}_a}{\mathcal{R}_0}. \quad (17)$$

For simulations of the combined model, we start by fixing the reproduction number of individuals who will eventually develop symptoms: $\mathcal{R}_{\text{symp}} = \mathcal{R}_p + \mathcal{R}_s = 4$. Consistent with previous assumptions, we also assume that asymptomatic reproduction number is lower than that of the symptomatic reproduction number: $\mathcal{R}_a = \rho\mathcal{R}_s$ where $\rho = 0.75$. Then, for a given value of the proportion of non-symptomatic transmission ϕ and proportion of non-symptomatic transmission caused by the pre-symptomatic transmission, $\eta = \mathcal{R}_p/(\mathcal{R}_p + p\mathcal{R}_a)$, we can solve for the transmission rate for each compartment β and the proportion asymptomatic p . More specifically:

$$\mathcal{R}_p = \frac{\mathcal{R}_{\text{symp}}}{1 + y} \quad (18)$$

$$\mathcal{R}_s = \mathcal{R}_{\text{symp}} - \mathcal{R}_p \quad (19)$$

$$\mathcal{R}_a = \rho\mathcal{R}_s \quad (20)$$

$$p = \left(\frac{1}{\eta} - 1\right) \frac{\mathcal{R}_p}{\mathcal{R}_a}, \quad (21)$$

319 where $y = (1/\phi - 1)/\eta + (1/\eta - 1)/\rho$. In order to keep the mean infectious period
320 fixed, we assume $1/\sigma = 2$ days and $1/\gamma_s = 1/\gamma_a = 3$ days. All other parameters are
321 same as before.

322 **Epidemic models with asymptomatic infection and transmis-**
323 **sion in the presence of immunity**

We then model the spread of infection in a partially immune population. The model dynamics are as follows:

$$\dot{S} = -\lambda(t)S \quad (22)$$

$$\dot{E} = \lambda(t)S - \nu E \quad (23)$$

$$\dot{I}_a = p\nu E - \gamma_a I_a \quad (24)$$

$$\dot{I}_s = (1-p)\nu E - \gamma_s I_s \quad (25)$$

$$\dot{R} = \gamma_a I_a + (1-f)\gamma_s I_s \quad (26)$$

$$\dot{D} = f\gamma_s I_s \quad (27)$$

$$\dot{S}_p = -(1-\epsilon_i)\lambda(t)S_p \quad (28)$$

$$\dot{E}_p = (1-\epsilon_i)\lambda(t)S_p - \nu E_p \quad (29)$$

$$\dot{I}_{p,a} = (1-(1-\epsilon_s)(1-p))\nu E_p - \gamma_a I_{p,a} \quad (30)$$

$$\dot{I}_{p,s} = (1-\epsilon_s)(1-p)\nu E_p - \gamma_s I_{p,s} \quad (31)$$

$$\dot{R}_p = \gamma_a I_{p,a} + (1-(1-\epsilon_d)f)\gamma_s I_{p,s} \quad (32)$$

$$\dot{D}_p = (1-\epsilon_d)f\gamma_s I_{p,s} \quad (33)$$

324 where $0 \leq \epsilon \leq 1$ represents the degree of protection against infection, symptoms and
325 death. The force of infection $\lambda(t)$ is given by:

$$\lambda(t) = \beta_a(I_a + I_{p,a}) + (1-\delta)\beta_s(I_s + I_{p,s}). \quad (34)$$

326 Here, subscripts p denote individuals who are immune and therefore are protected.

327 Supplementary Tables

Parameter	Description	Assumed values
β_s	Symptomatic transmission rate	0.8/days
β_a	Asymptomatic transmission rate	$0.75\beta_s$
$1/\nu$	Mean latent period	2 days
$1/\gamma_s$	Mean symptomatic infectious period	5 days
$1/\gamma_a$	Mean asymptomatic infectious period	5 days
p	Proportion asymptomatic	0–1
f	Fatality rate for symptomatic case	0.01
δ	Reduction in symptomatic transmission rate	0–1

Table S1: Parameter descriptions and values for the basic asymptomatic model.

Parameter	Description	Assumed values
β_s	Symptomatic transmission rate	See Supplementary Text
β_a	Asymptomatic transmission rate	See Supplementary Text
β_p	Presymptomatic transmission rate	See Supplementary Text
$1/\nu$	Mean latent period	2 days
$1/\sigma$	Mean presymptomatic infectious period	2 days
$1/\gamma_s$	Mean symptomatic infectious period	3 days
$1/\gamma_a$	Mean asymptomatic infectious period	3 days
p	Proportion asymptomatic	0–1
f	Fatality rate for symptomatic case	0.01
δ	Reduction in symptomatic transmission rate	0–1

Table S2: Parameter descriptions and values for the generalized asymptomatic model.

Parameter	Description	Assumed values
β_s	Symptomatic transmission rate	0.8/days
β_a	Asymptomatic transmission rate	$0.75\beta_s$
$1/\nu$	Mean latent period	2 days
$1/\gamma_s$	Mean symptomatic infectious period	5 days
$1/\gamma_a$	Mean asymptomatic infectious period	5 days
p	Proportion asymptomatic	0–1
f	Fatality rate for symptomatic case	0.01
δ	Reduction in symptomatic transmission rate	0–1
ϵ_i	Protection against infection	0–0.8
ϵ_s	Protection against symptoms	0–0.8
ϵ_d	Protection against deaths	0–0.8

Table S3: Parameter descriptions and values for the asymptomatic model with immunity.

328 **Supplementary Figures**




Figure S1: **Schematic diagram and simulations of a model with pre-symptomatic and asymptomatic transmission and symptom-responsive transmission reduction.** (A) S represents susceptible individuals; E represents exposed individuals; I_p represents pre-symptomatic individuals; I_a represents symptomatic individuals; I_s represents symptomatic individuals; R represents recovered individuals; and D represents deceased individuals. See Methods for model details. (B) Total deaths as a function of the proportion of non-symptomatic transmission ϕ across a wide range scenarios for δ and proportion of non-symptomatic transmission caused by the pre-symptomatic transmission, η (between 0% and 100%). See Supplementary Text for model details and Supplementary Table S2 for parameter descriptions and values.

329 References

- 330 [1] Bianca Nogrady. What the data say about asymptomatic COVID infections.
331 *Nature*, 587(7835):534–536, 2020.
- 332 [2] Dimple D Rajgor, Meng Har Lee, Sophia Archuleta, Natasha Bagdasarian, and
333 Swee Chye Quek. The many estimates of the COVID-19 case fatality rate. *The*
334 *Lancet Infectious Diseases*, 20(7):776–777, 2020.
- 335 [3] Robert Verity, Lucy C Okell, Ilaria Dorigatti, Peter Winskill, Charles Whit-
336 taker, Natsuko Imai, Gina Cuomo-Dannenburg, Hayley Thompson, Patrick G T
337 Walker, Han Fu, Amy Dighe, Jamie T Griffin, Marc Baguelin, Sangeeta Bha-
338 tia, Adhiratha Boonyasiri, Anne Cori, Zulma Cucunubá, Rich FitzJohn, Katy
339 Gaythorpe, Will Green, Arran Hamlet, Wes Hinsley, Daniel Laydon, Gemma
340 Nedjati-Gilani, Steven Riley, Sabine van Elsland, Erik Volz, Haowei Wang,
341 Yuanrong Wang, Xiaoyue Xi, Christl A Donnelly, Azra C Ghani, and Neil M
342 Ferguson. Estimates of the severity of coronavirus disease 2019: a model-based
343 analysis. *The Lancet Infectious Diseases*, 20(6):669–677, 2020.
- 344 [4] Shu Yang, Peihua Cao, Peipei Du, Ziting Wu, Zian Zhuang, Lin Yang, Xuan Yu,
345 Qi Zhou, Xixi Feng, Xiaohui Wang, Weiguo Li, Enmei Liu, Ju Chen, Yaolong
346 Chen, and Daihai He on behalf of COVID-19 evidence and recommendations
347 working group. Early estimation of the case fatality rate of COVID-19 in main-
348 land China: a data-driven analysis. *Annals of translational medicine*, 8(4), 2020.
- 349 [5] Andrew T Levin, William P Hanage, Nana Owusu-Boaitey, Kensington B
350 Cochran, Seamus P Walsh, and Gideon Meyerowitz-Katz. Assessing the age
351 specificity of infection fatality rates for COVID-19: systematic review, meta-
352 analysis, and public policy implications. *European journal of epidemiology*,
353 35(12):1123–1138, 2020.
- 354 [6] Jon C Emery, Timothy W Russell, Yang Liu, Joel Hellewell, Carl AB Pearson,
355 CMMID COVID-19 Working Group, Gwenan M Knight, Rosalind M Eggo,
356 Adam J Kucharski, Sebastian Funk, Stefan Flasche, and Rein MGJ Houben.
357 The contribution of asymptomatic SARS-CoV-2 infections to transmission on
358 the Diamond Princess cruise ship. *eLife*, 9:e58699, aug 2020.
- 359 [7] Stephen M. Kissler, Joseph R. Fauver, Christina Mack, Scott W. Olesen, Car-
360 oline Tai, Kristin Y. Shiue, Chaney C. Kalinich, Sarah Jednak, Isabel M. Ott,
361 Chantal B.F. Vogels, Jay Wohlgemuth, James Weisberger, John DiFiori, Dev-
362 erick J. Anderson, Jimmie Mancell, David D. Ho, Nathan D. Grubaugh, and
363 Yonatan H. Grad. Viral dynamics of acute SARS-CoV-2 infection. *medRxiv*,
364 2021.
- 365 [8] Nicholas G. Davies, Petra Klepac, Yang Liu, Kiesha Prem, Mark Jit, Ros-
366 alind M. Eggo, and CMMID COVID-19 working group. Age-dependent ef-

- 367 facts in the transmission and control of COVID-19 epidemics. *Nature Medicine*,
368 26(8):1205–1211, 2020.
- 369 [9] Kenji Mizumoto, Katsushi Kagaya, Alexander Zarebski, and Gerardo Chowell.
370 Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-
371 19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.
372 *Eurosurveillance*, 25(10):2000180, 2020.
- 373 [10] Luca Ferretti, Chris Wymant, Michelle Kendall, Lele Zhao, Anel Nurtay, Lucie
374 Abeler-Dörner, Michael Parker, David Bonsall, and Christophe Fraser. Quanti-
375 fying SARS-CoV-2 transmission suggests epidemic control with digital contact
376 tracing. *Science*, 368(6491):eabb6936, 2020.
- 377 [11] Enrico Lavezzo, Elisa Franchin, Constanze Ciavarella, Gina Cuomo-
378 Dannenburg, Luisa Barzon, Claudia Del Vecchio, Lucia Rossi, Riccardo Man-
379 ganelli, Arianna Loregian, Nicolò Navarin, Davide Abate, Manuela Sciro, Ste-
380 fano Merigliano, Ettore De Canale, Maria Cristina Vanuzzo, Valeria Besutti,
381 Francesca Saluzzo, Francesco Onelia, Monia Pacenti, Saverio G. Parisi, Giovanni
382 Carretta, Daniele Donato, Luciano Flor, Silvia Cocchio, Giulia Masi, Alessan-
383 dro Sperduti, Lorenzo Cattarino, Renato Salvador, Michele Nicoletti, Federico
384 Caldart, Gioele Castelli, Eleonora Nieddu, Beatrice Labella, Ludovico Fava,
385 Matteo Drigo, Katy A. M. Gaythorpe, Alessandra R. Brazzale, Stefano Toppo,
386 Marta Trevisan, Vincenzo Baldo, Christl A. Donnelly, Neil M. Ferguson, Ilaria
387 Dorigatti, Andrea Crisanti, Kylie E. C. Ainslie, Marc Baguelin, Samir Bhatt,
388 Adhiratha Boonyasiri, Olivia Boyd, Helen L. Coupland, Zulma Cucunubá, Bi-
389 mandra A. Djafaara, Christl A. Donnelly, Sabine L. van Elsland, Rich FitzJohn,
390 Seth Flaxman, Katy A. M. Gaythorpe, Will D. Green, Timothy Hallett, Arran
391 Hamlet, David Haw, Natsuko Imai, Benjamin Jeffrey, Edward Knock, Daniel J.
392 Laydon, Thomas Mellan, Swapnil Mishra, Gemma Nedjati-Gilani, Pierre Nou-
393 vellet, Lucy C. Okell, Kris V. Parag, Steven Riley, Hayley A. Thompson, H. Juli-
394 ette T. Unwin, Robert Verity, Michaela A. C. Vollmer, Patrick G. T. Walker,
395 Caroline E. Walters, Haowei Wang, Yuanrong Wang, Oliver J. Watson, Charles
396 Whittaker, Lilith K. Whittles, Xiaoyue Xi, Neil M. Ferguson, and Imperial Col-
397 lege COVID-19 Response Team. Suppression of a sars-cov-2 outbreak in the
398 italian municipality of vo'. *Nature*, 584(7821):425–429, 2020.
- 399 [12] María Pilar Romero-Gómez, Silvia Gómez-Sebastian, Emilio Cendejas-Bueno,
400 María Dolores Montero-Vega, Jesús Mingorance, and Julio García-Rodríguez.
401 Ct value is not enough to discriminate patients harbouring infective virus. *Jour-
402 nal of Infection*, 82(3):e35–e37, 2021.
- 403 [13] Muluneh Alene, Lelteswork Yismaw, Moges Agazhe Assemie, Daniel Bekele
404 Ketema, Belayneh Mengist, Bekalu Kassie, and Tilahun Yemanu Birhan. Mag-
405 nitude of asymptomatic COVID-19 cases throughout the course of infection: A
406 systematic review and meta-analysis. *PloS one*, 16(3):e0249090, 2021.

- 407 [14] Christophe Fraser, Steven Riley, Roy M Anderson, and Neil M Ferguson. Fac-
408 tors that make an infectious disease outbreak controllable. *Proceedings of the*
409 *National Academy of Sciences*, 101(16):6146–6151, 2004.
- 410 [15] Yan Xie, Evan Xu, Benjamin Bowe, and Ziyad Al-Aly. Long-term cardiovascular
411 outcomes of COVID-19. *Nature medicine*, 28(3):583–590, 2022.
- 412 [16] Xi He, Eric H. Y. Lau, Peng Wu, Xilong Deng, Jian Wang, Xinxin Hao,
413 Yiu Chung Lau, Jessica Y. Wong, Yujuan Guan, Xinghua Tan, Xiaoneng Mo,
414 Yanqing Chen, Baolin Liao, Weilie Chen, Fengyu Hu, Qing Zhang, Mingqiu
415 Zhong, Yanrong Wu, Lingzhai Zhao, Fuchun Zhang, Benjamin J. Cowling, Fang
416 Li, and Gabriel M. Leung. Temporal dynamics in viral shedding and transmis-
417 sibility of COVID-19. *Nature Medicine*, 26(5):672–675, 2020.
- 418 [17] Ron Sender, Yinon M Bar-On, Sang Woo Park, Elad Noor, Jonathan Dushoffd,
419 and Ron Milo. The unmitigated profile of COVID-19 infectiousness. *medRxiv*,
420 2021.
- 421 [18] Marc Lipsitch and Natalie E Dean. Understanding COVID-19 vaccine efficacy.
422 *Science*, 370(6518):763–765, 2020.
- 423 [19] Nick Andrews, Julia Stowe, Freja Kirsebom, Samuel Toffa, Tim Rickeard,
424 Eileen Gallagher, Charlotte Gower, Meaghan Kall, Natalie Groves, Anne-
425 Marie O’Connell, David Simons, Paula B. Blomquist, Asad Zaidi, Sophie Nash,
426 Nurin Iwani Binti Abdul Aziz, Simon Thelwall, Gavin Dabrera, Richard My-
427 ers, Gayatri Amirthalingam, Saheer Gharbia, Jeffrey C. Barrett, Richard Elson,
428 Shamez N. Ladhani, Neil Ferguson, Maria Zambon, Colin N.J. Campbell, Kevin
429 Brown, Susan Hopkins, Meera Chand, Mary Ramsay, and Jamie Lopez Bernal.
430 Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. *New*
431 *England Journal of Medicine*, 386(16):1532–1546, 2022.
- 432 [20] Carl A. B. Pearson, Sheetal P. Silal, Michael W.Z. Li, Jonathan Dushoff,
433 Benjamin M. Bolker, Sam Abbott, Cari van Schalkwyk, Nicholas G. Davies,
434 Rosanna C. Barnard, W. John Edmunds, Jeremy Bingham, Gesine Meyer-Rath,
435 Lise Jamieson, Allison Glass, Nicole Wolter, Nevashan Govender, Wendy S.
436 Stevens, Lesley Scott, Koleka Mlisana, Harry Moultrie, and Juliet R. C. Pul-
437 liam. Bounding the levels of transmissibility & immune evasion of the Omicron
438 variant in South Africa. *medRxiv*, 2021.
- 439 [21] Kaiyuan Sun, Stefano Tempia, Jackie Kleynhans, Anne von Gottberg, Mered-
440 ith L McMorro, Nicole Wolter, Jinal N. Bhiman, Jocelyn Moyes, Mignon du
441 Plessis, Maimuna Carrim, Amelia Buys, Neil A Martinson, Kathleen Kahn,
442 Stephen Tollman, Limakatso Lebina, Floidy Wafawanaka, Jacques D. du Toit,
443 Francesc Xavier Gómez-Olivé, Thulisa Mkhencele, Cécile Viboud, Cheryl Co-
444 hen, and the PHIRST group. Persistence of SARS-CoV-2 immunity, Omicron’s

- 445 footprints, and projections of epidemic resurgences in South African population
446 cohorts. *medRxiv*, 2022.
- 447 [22] Cristina Menni, Ana M Valdes, Lorenzo Polidori, Michela Antonelli, Satya Penam
448 makuri, Ana Nogal, Panayiotis Louca, Anna May, Jane C Figueiredo, Christina
449 Hu, Erika Molteni, Liane Canas, Marc F Österdahl, Marc Modat, Carole H Sud
450 dre, Ben Fox, Alexander Hammers, Jonathan Wolf, Joan Capdevila, Andrew T
451 Chan, Sean P David, Claire J Steves, Sebastien Ourselin, and Tim D Spector.
452 Symptom prevalence, duration, and risk of hospital admission in individuals
453 infected with SARS-CoV-2 during periods of omicron and delta variant domi
454 nance: a prospective observational study from the ZOE COVID Study. *The*
455 *Lancet*, 399(10335):1618–1624, 2022.
- 456 [23] Ana Cecilia Ulloa, Sarah A Buchan, Nick Daneman, and Kevin A Brown. Es
457 timates of SARS-CoV-2 omicron variant severity in Ontario, Canada. *Jama*,
458 327(13):1286–1288, 2022.
- 459 [24] Gareth Iacobucci. Covid-19: unravelling the conundrum of Omicron and deaths.
460 *BMJ*, 376, 2022.
- 461 [25] Jeremy Samuel Faust, Chengan Du, Chenxue Liang, Katherine Dickerson
462 Mayes, Benjamin Renton, Kristen Panthagani, and Harlan M. Krumholz. Excess
463 Mortality in Massachusetts During the Delta and Omicron Waves of COVID-19.
464 *JAMA*, 05 2022.
- 465 [26] Alex Sigal, Ron Milo, and Waasila Jassat. Estimating disease severity of Omi
466 cron and Delta SARS-CoV-2 infections. *Nature Reviews Immunology*, pages 1–3,
467 2022.
- 468 [27] Chadi M Saad-Roy, Caroline E Wagner, Rachel E Baker, Sinead E Morris,
469 Jeremy Farrar, Andrea L Graham, Simon A Levin, Michael J Mina, C Jes
470 sica E Metcalf, and Bryan T Grenfell. Immune life history, vaccination, and the
471 dynamics of SARS-CoV-2 over the next 5 years. *Science*, 370(6518):811–818,
472 2020.
- 473 [28] Sang Woo Park, Daniel M Cornforth, Jonathan Dushoff, and Joshua S Weitz.
474 The time scale of asymptomatic transmission affects estimates of epidemic po
475 tential in the COVID-19 outbreak. *Epidemics*, 31:100392, 2020.
- 476 [29] Jeremy D Harris, Sang Woo Park, Jonathan Dushoff, and Joshua S Weitz. How
477 time-scale differences in asymptomatic and symptomatic transmission shape
478 SARS-CoV-2 outbreak dynamics. *medRxiv*, 2022.
- 479 [30] Sam Moore, Edward M Hill, Louise Dyson, Michael J Tildesley, and Matt J
480 Keeling. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK.
481 *PLoS computational biology*, 17(5):e1008849, 2021.

- 482 [31] Katia Koelle, Michael A Martin, Rustom Antia, Ben Lopman, and Natalie E
483 Dean. The changing epidemiology of SARS-CoV-2. *Science*, 375(6585):1116–
484 1121, 2022.
- 485 [32] Aroon Chande, Seolha Lee, Mallory Harris, Quan Nguyen, Stephen J Beckett,
486 Troy Hilley, Clio Andris, and Joshua S Weitz. Real-time, interactive website for
487 US-county-level COVID-19 event risk assessment. *Nature Human Behaviour*,
488 4(12):1313–1319, 2020.
- 489 [33] Alyssa H Sinclair, Shabnam Hakimi, Matthew L Stanley, R Alison Adcock, and
490 Gregory R Samanez-Larkin. Pairing facts with imagined consequences improves
491 pandemic-related risk perception. *Proceedings of the National Academy of Sci-*
492 *ences*, 118(32):e2100970118, 2021.
- 493 [34] Michael J Mina and Kristian G Andersen. COVID-19 testing: One size does
494 not fit all. *Science*, 371(6525):126–127, 2021.
- 495 [35] Greg Gibson, Joshua S. Weitz, Michael P. Shannon, Benjamin Holton, An-
496 ton Bryksin, Brian Liu, Madeline Sieglinger, Ashley R. Coenen, Conan Zhao,
497 Stephen J. Beckett, Sandra Bramblett, JulieAnne Williamson, Michael Farrell,
498 Alexander Ortiz, Chaouki T. Abdallah, and Andrés J. García. Surveillance-to-
499 diagnostic testing program for asymptomatic SARS-CoV-2 infections on a large,
500 urban campus in fall 2020. *Epidemiology*, 33(2), 2022.
- 501 [36] Nicholas R Jones, Zeshan U Qureshi, Robert J Temple, Jessica PJ Larwood,
502 Trisha Greenhalgh, and Lydia Bourouiba. Two metres or one: what is the
503 evidence for physical distancing in COVID-19? *bmj*, 370, 2020.
- 504 [37] Kimberly A Prather, Chia C Wang, and Robert T Schooley. Reducing trans-
505 mission of SARS-CoV-2. *Science*, 368(6498):1422–1424, 2020.
- 506 [38] Jeremy Howard, Austin Huang, Zhiyuan Li, Zeynep Tufekci, Vladimir Zdimal,
507 Helene-Mari van der Westhuizen, Arne von Delft, Amy Price, Lex Fridman, Lei-
508 Han Tang, Viola Tang, Gregory L. Watson, Christina E. Bax, Reshama Shaikh,
509 Frederik Questier, Danny Hernandez, Larry F. Chu, Christina M. Ramirez,
510 and Anne W. Rimoin. An evidence review of face masks against COVID-19.
511 *Proceedings of the National Academy of Sciences*, 118(4):e2014564118, 2021.
- 512 [39] Joseph G Allen and Andrew M Ibrahim. Indoor air changes and potential
513 implications for SARS-CoV-2 transmission. *Jama*, 325(20):2112–2113, 2021.
- 514 [40] Chia C Wang, Kimberly A Prather, Josué Sznitman, Jose L Jimenez, Seema S
515 Lakdawala, Zeynep Tufekci, and Linsey C Marr. Airborne transmission of res-
516 piratory viruses. *Science*, 373(6558):eabd9149, 2021.

- 517 [41] Benjamin A Lopman, Kayoko Shioda, Quan Nguyen, Stephen J Beckett,
518 Aaron J Siegler, Patrick S Sullivan, and Joshua S Weitz. A framework for moni-
519 toring population immunity to SARS-CoV-2. *Annals of Epidemiology*, 63:75–78,
520 2021.
- 521 [42] Sang Woo Park, Benjamin M Bolker, David Champredon, David JD Earn,
522 Michael Li, Joshua S Weitz, Bryan T Grenfell, and Jonathan Dushoff. Rec-
523 onciling early-outbreak estimates of the basic reproductive number and its un-
524 certainty: framework and applications to the novel coronavirus (SARS-CoV-2)
525 outbreak. *Journal of the Royal Society Interface*, 17(168):20200144, 2020.